alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

27,780 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 151–175 of 195 studies with an author at UNSW Sydney (AU) (page 7 of 8) · 27,780 in the whole library · How the 0–100 score works

Download bibliography of these 195 studies, in this order: BibTeX (.bib) · RIS (.ris)

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Other institutions

From OpenAlex; 13,259 studies have no institution on record and are not counted here.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Common risk factors for major noncommunicable disease, a systematic overview of reviews and commentary: the implied potential for targeted risk reduction

✓ Peer-reviewed alzhub usefulness score 48 out of 100. Therapeutic advances in chronic disease 2019-10-15

Noncommunicable disease now contributes to the World Health Organization top 10 causes of death in low-, middle- and high-income countries. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Obesity and cognitive decline: role of inflammation and vascular changes

✓ Peer-reviewed alzhub usefulness score 48 out of 100. Frontiers in neuroscience 2014-11-19

The incidence of obesity in middle age is increasing markedly, and in parallel the prevalence of metabolic disorders including cardiovascular disease and type II diabetes is also rising. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

New criteria for frontotemporal dementia syndromes: clinical and pathological diagnostic implications

✓ Peer-reviewed alzhub usefulness score 48 out of 100. Journal of neurology, neurosurgery, and psychiatry 2014-01-13

This study provides pathological validation that the new criteria assist with separating PPA cases with AD pathology into the new lv-PPA syndrome and found that a number of diagnostic clinical features (disinhibition, food preferences and naming) did not assist in discriminating the different FTD syndromes. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Key lessons to improve care—factors contributing to delayed discharges and cost implications: medical conditions and rehabilitation delays at a tertiary rehabilitation center in Saudi Arabia

✓ Peer-reviewed alzhub usefulness score 48 out of 100. International Journal for Quality in Health Care 2024-04-01

TBI had the highest percentage (37%) compared to other conditions, which may be attributed to the prevalent challenge of cognitive impairment in TBI in addition to physical disability. 5 key findings →

Design: cohort study Participants: 2,285 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Toward ‘net zero’ hysterectomy for Australia; New Zealand is already heading there…

✓ Peer-reviewed alzhub usefulness score 48 out of 100. Australian and New Zealand Journal of Obstetrics and Gynaecology 2022-02-01

Hysterectomy is often recommended for gynaecological symptomatology because menstruation inevitably ceases, and the mortality rate associated with this operation is low3. 5 key findings →

Design: cohort study Evidence: high

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Immunohistochemical evaluation of a trial of gantenerumab or solanezumab in dominantly inherited Alzheimer disease

✓ Peer-reviewed alzhub usefulness score 48 out of 100. Acta Neuropathologica 2025-06-03

Clinical trials of anti-amyloid-β (Aβ) monoclonal antibodies in Alzheimer disease (AD) infer target engagement from Aβ positron emission tomography (PET) and/or fluid biomarkers such as cerebrospinal fluid (CSF) Aβ42/40. 2 key findings →

Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Vascular cognitive impairment and dementia: Prevention, treatments, mechanisms and management options for the future

✓ Peer-reviewed alzhub usefulness score 48 out of 100. Neuropsychopharmacology 2026-01-19

Vascular Cognitive Impairment and Dementia (VCID), the second most common form of dementia, is becoming increasingly prevalent worldwide. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Recent evidence for an expanded role of the kynurenine pathway of tryptophan metabolism in neurological diseases

✓ Peer-reviewed alzhub usefulness score 47 out of 100. Neuropharmacology 2016-03-16

The kynurenine pathway (KP) of tryptophan metabolism has emerged in recent years as a key regulator of the production of both neuroprotective (e.g. kynurenic and picolinic acid, and the essential cofactor NAD+) and neurotoxic metabolites (e.g. quinolinic acid, 3-hydroxykynurenine). 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Logopenic and nonfluent variants of primary progressive aphasia are differentiated by acoustic measures of speech production

✓ Peer-reviewed alzhub usefulness score 47 out of 100. PloS one 2014-02-28

Differentiation of logopenic (lvPPA) and nonfluent/agrammatic (nfvPPA) variants of Primary Progressive Aphasia is important yet remains challenging since it hinges on expert based evaluation of speech and language production. 3 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Sex and socioeconomic differences in 15-year prevalence trends for modifiable dementia risk factors in Australia: a cross-sectional, time series analysis

✓ Peer-reviewed alzhub usefulness score 47 out of 100. The Lancet Healthy Longevity 2025-05-01

In mid-life, the sample sizes ranged from 4100 in 2022 to 5589 in 2017-18 and in late-life from 2799 in 2011-12 to 3762 in 2017-18. 5 key findings →

Design: cross-sectional Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Identifying dementia risk profiles for targeted interventions: A latent class analysis of at‐risk middle‐aged Australians

✓ Peer-reviewed alzhub usefulness score 47 out of 100. Alzheimer s & Dementia 2025-11-01

Among 403 participants (mean age 56.4 ± 5.7 years, 62.5% female), the median number of dementia risk factors was 5.0; hyperlipidaemia (92.5%), low cognitive activity (72.5%), obesity (57.6%), and hypertension (52.7%) were the most prevalent. 5 key findings →

Design: cross-sectional Participants: 403 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Diet, inflammation and the gut microbiome: Mechanisms for obesity-associated cognitive impairment

✓ Peer-reviewed alzhub usefulness score 46 out of 100. Biochimica et biophysica acta. Molecular basis of disease 2020-03-18

Poor diet and obesity are associated with cognitive impairment throughout adulthood, and increased dementia risk in aging. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Kynurenine pathway metabolism in human astrocytes: a paradox for neuronal protection

✓ Peer-reviewed alzhub usefulness score 46 out of 100. Journal of neurochemistry 2001-08-01

There is good evidence that the kynurenine pathway (KP) and one of its products, quinolinic acid (QUIN), play a role in the pathogenesis of neurological diseases, in particular AIDS dementia complex. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Can progressive and non-progressive behavioural variant frontotemporal dementia be distinguished at presentation?

✓ Peer-reviewed alzhub usefulness score 45 out of 100. Journal of neurology, neurosurgery, and psychiatry 2009-02-18

Progressive and non-progressive patients are difficult to differentiate on the basis of current clinical diagnostic criteria for FTD but a combination of general cognitive, executive dysfunction and impaired ADL measures appear to be the most promising discriminators. 2 key findings →

Participants: 71 Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 27,780 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,780 records, built mostly from automated pulls of Europe PMC (61.1% of the library) and OpenAlex (18.3%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed